Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial

Arthritis and Rheumatism

Volumn 58, Issue 6, 2008, Pages 1687-1695

  Reginster, Jean Yves ^a,n   Felsenberg, Dieter ^b   Boonen, Steven ^c   Diez Perez, Adolfo ^d   Rizzoli, Rene ^e   Brandi, Maria Luisa ^f   Spector, Tim D ^g   Brixen, Kim ^h   Goemaere, Stefan ⁱ   Cormier, Catherine ^j   Balogh, Adam ^k   Delmas, Pierre D ^l   Meunier, Pierre J ^m  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d HOSPITAL DEL MAR   (Spain)

^e Hôpital Cantonal   (Switzerland)

^f Policlinico Careggi   (Italy)

^g ST THOMAS HOSPITAL   (United Kingdom)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j Hôpital Cochin ^*  (France)

^k UNIVERSITY OF DEBRECEN   (Hungary)

^l INSERM   (France)

^m UNIVERSITÉ LYON 1   (France)

ⁿ UNIVERSITY OF LIÈGE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; STRONTIUM RANELATE;

AGED; ARTICLE; BONE DENSITY; BONE RADIOGRAPHY; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FEMALE; FEMUR NECK; FRACTURE REDUCTION; HEADACHE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; POST HOC ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SPINE RADIOGRAPHY; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; LONGITUDINAL STUDIES; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL INJURIES; THIOPHENES; TREATMENT OUTCOME;

EID: 45349090543     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23461     Document Type: Article

References (30)

1. Cummings SR, Melton LJ III. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7.
2. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997;7:407-13.
3. Schwenkglenks M, Lippuner K, Hauselmann HJ, Szucs TD. A model of osteoporosis impact in Switzerland 2000-2020. Osteoporos Int 2005;16:659-71.
4. Puffer S, Torgerson DJ, Sykes D, Brown P, Cooper C. Healthcare costs of women with symptomatic vertebral fractures. Bone 2004;35:383-6.
5. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-61.
6. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121-9.
7. Buehler J, Chappuis P, Saffar JL, Tsouderos Y, Vignery A. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001;29:176-9.
8. Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002;450:11-7.
9. Marie PJ. Strontium ranelate: a novel mode of action of optimizing bone formation and resorption. Osteoporos Int 2005;16 Suppl 1:S7-10.
10. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.
11. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22.
12. Meunier PJ, Reginster JY. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int 2003;14 Suppl 3:S66-76.
13. Melton LJ III, Thamer M, Ray NF, Chan JK, Chestnut CH III, Einhorn TA, et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:16-23.
14. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-48.
15. Slosman DO, Prowedini DM, Meunier PJ, Delmas PD, Sebert JL, de Vernejoul MC, et al. The use of different dual x-ray absorptiometry brands in a multicenter clinical trial. J Clin Densitom 1999;2:37-44.
16. Nielsen SP, Slosman D, Sorensen OH, Basse-Cathalinat B, De Cassin P, Roux CR, et al. Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J Clin Densitom 1999;2:371-9.
17. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Mortality after osteoporotic fractures. Osteoporos Int 2004;15:38-42.
18. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al, the Fracture Intervention Trial Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
19. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, et al, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomised clinical trial. J Clin Endocrinol Metab 2002;87:3609-17.
20. Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120-6.
21. Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8.
22. Black D, Schwartz A, Ensrud K, Cauley JA, Levis S, Quandt SA, et al, for the FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX), a randomized trial. JAMA 2006;296:2927-38.
23. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, et al, for the Fracture Intervention Trial long-term extension. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial Long-Term Extension Research Group. J Bone Miner Res 2004;19:1259-69.
24. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales A, Menkes CJ, Wasnich RD, et al, for the Phase III Osteoporosis Treatment Study Group. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000;85:3109-15.
25. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al, for the Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.
26. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, et al, for the Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-24.
27. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al, for the Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37.
28. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al, the Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
29. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al, for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-52.
30. Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al, Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.